On Monday, March 2, 2026, Shattuck Labs (NASDAQ:STTK) showcased its innovative approach to treating inflammatory bowel disease (IBD) at the TD Cowen 46th Annual Health Care Conference. CEO Taylor ...
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company’s lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory ...
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The ...
Shattuck Labs Inc. has announced a strategic shift to focus on SL-325, a death receptor 3 (DR3) antagonist antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory ...
Inflammatory bowel disease (IBD) is a chronic condition that currently does not have a cure. However, certain lifestyle measures, such as keeping an IBD journal, can help you track symptoms, identify ...
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, remains a major clinical challenge owing to its complex pathophysiology and clinical management: it is a ...
Inflammatory Bowel Disease (IBD) is a chronic disease of inflammation along the digestive tract. There are two forms of IBD, including Crohn’s disease and ulcerative colitis. Symptoms include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results